August 2026 FDA Recall Olanzapine by Macleods Pharmaceuticals Limited
D-0867-2026 - Failed Impurities/Degradation Specifications

This Class III drug recall was voluntarily initiated by Macleods Pharmaceuticals Limited on August 27, 2026 for the product Olanzapine. The FDA reported the reason for recall as failed impurities/degradation specifications. The product was distributed Nationwide and the recall is currently ongoing.

Recall Number: D-0867-2026

Reason for Recall
Failed Impurities/Degradation Specifications:Organic and unspecified impurities above specification.
Initiated
08-27-2026
Reported
09-30-2026
Quantity
22,032 30-count bottles

Recall Profile & Regulatory Data

Class III - is a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences.
Macleods Pharmaceuticals Limited
Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Nationwide in the USA
Olanzapine Tablets, USP 5 mg, 30-count bottle, Rx Only, Manufactured For: Macleods Pharma USA, Inc. Princeton, NJ, 08540; Manufactured by: Macleods Pharmaceuticals, Ltd, Baddi, Himachal Pradesh, INDIA, NDC 33342-068-07.

Batch or Lot Expiration Information

Lot# Lot: BOB22321A, Exp 07-31-2027.